The efficiency of non-specific inhaled immunotherapy with ruzam in patients with atopic bronchialasthma

Background. To study the efficacy and safety of inhaled form of ruzam in adult patients with persistent mild and moderate atopic bronchial asthma (ba). Materials and methods. a placebo-controlled prospective, randomized, open label study of an efficacy of ruzam a solution for inhalations (in bottles on 2,5 or 5 ml) on 2,5 ml onсe a day through nebulizer during 2 weeks was conducted in adult asthmatic patients. The efficacy of therapy was evaluated by dynamics of symptoms and requirement in ƒ2-agonists, besides PEfr, spirometry, bronchial hyperresponsiveness (bhr), asthma control test (aCT ), level of the markers of the allergic inflammation were performed. Results. reduction of bа symptoms, increase morning PEfr, decrease of bhr and NОex level in patients who received ruzam compared with control group was observed. achievement of clinical control of bа in patients treated by ruzam was accompanied by statistically significant positive dynamics of markers of inflammation (ifNg, ECP) in blood serum and in supernatant of the induced sputum. it testifies about anti-inflammatory influence of ruzam. Conclusion. inhaled therapy with ruzam in a complex with iNCs basic therapy is an effective and safe method of treatment of persistent atopic bronchial asthma. This combination allows to reach clinical and functional control of ba faster and to reduce inflammation markers in blood serum and induced sputum.